---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-142885"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:12:59.377404+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M

## Summary
- 12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.
- Gross proceeds $17.5M; net proceeds ~$16M after underwriting discounts and expenses.
- Underwriters granted 30-day option to buy up to 1.875M additional shares and warrants.
- Series A warrants expire in 1 year, Series B warrants in 5 years; beneficial ownership cap 4.99%.
- Closing expected April 6, 2026; Piper Sandler sole book-running manager.

## SEC filing metadata
- accession: 0001193125-26-142885
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/0001193125-26-142885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/d137120d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-142885
- JSON: https://secwatch.observer/filing/0001193125-26-142885.json
- Plain text: https://secwatch.observer/filing/0001193125-26-142885.txt

## Source-grounded claims
- claim_id: f91b20a94d21b3dddb6ddcc2c57433d7185ebe90
  claim: INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Piper Sandler & Co. valued at Public offering of 12,500,000 shares of common stock and Series A and Series B warrants with an opti (effective 2026-04-02).
  evidence_excerpt: On April 2, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in a public offering of 12,500,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and accompanying Series A warrants to purchase up to 12,500,000 shares of its Common Stock (or pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “ Pre-Funded Warrants ”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “ Series A Warrants ”) and Series B warrants to purchase up to 12,500,000 shares of its Common Stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of Common S
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312526142885/0001193125-26-142885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.